Replies to post #502194 on Anavex Life Sciences Corp (AVXL)

[georgejjl]

Doc328: Do you believe that the following is in general true or false???

Alzheimer's disease is easier to treat at the earliest stage possible.

The above is especially true if you are targeting upstream MOA with precision medicine.

See the image below to understand why this is true.


The Anavex Blarcamesine Phase 2b/3 trial is for early stage Alzheimer's disease with baseline MMSE scores of 20 to 28 inclusive

Prevention of Alzheimer's disease via Blarcamesine or Anavex 3-71 would be the earliest stage possible.

Good luck and GOD bless

[boi568]

The irony for Missling is that he could have chosen CDR-SB, which blarcamesine hit, as the co-primary functional endpoint for the 2b/3, rendering the current discussion moot. However, the use of CDR-SB as the prime secondary endpoint in the trial supports Anavex's multiplicity solution of p<.025 for both ADAS-Cog13 and CDR-SB.